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Background and Purpose:Home-Time is a stroke outcome measure based on time spent at home 
following stroke.  We hypothesised that Home-Time assessment would be feasible and valid using 
national data. 
 
Methods:We linked the Scottish Stroke Care Audit to routine healthcare data and calculated 90-day 
Home-Time for all strokes:2005-2017.  We described prognostic validity (Spearman rank correlation) 
of Home-Time to baseline factors.  
 
Results:We were able to calculate Home-Time for 101,969 strokes (99.3% of total Scottish strokes).  
Mean Home-Time was 46 days (95%CI:45.8 to 46.2; range:0-90).  Home-Time showed consistent 
correlation with our pre-specified prognostic factors, :age:rho-0.35 (95%CI:-0.35 to -0.36);NIHSS:-
0.54 (95%CI:-0.52 to -0.55);Six Simple Variables (ordinal):-0.61 (95%CI:-0.61 to -0.62).  
 
Conclusions:Home-Time can be derived at scale using routine clinical data and appears to be a valid 
proxy measure of functional recovery.  Other national databases could use Home-Time as a time and 
cost efficient measure of medium and longer term outcomes.  
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Introduction 
Robust measures of stroke functional outcome are required for clinical trials; observational 
epidemiology and quality improvement programs.1  The ideal measure should be relevant to 
patients/carers, responsive to change and widely available at low cost.  In person, detailed 
assessment may not be possible for large or geographically dispersed populations.  In trials we use 
modified Rankin Scale (mRS).  However, in large studies with limited resource, low response rate 
risks substantial attrition bias.  Thus, we need outcomes which approximate to mRS but which are 
available without direct follow up. 
 
Home-Time (HT) is a measure of the time spent back at the person’s home during a predefined 
period following a stroke.  It accounts for survival, time spent in hospital or rehabilitation settings; 
re-admission and institutionalisation.2  HT has been shown to be a valid marker of functional 
outcomes and is valued by people living with stroke.3   HT is an attractive measure for population 
studies, but to date validation has been limited to trials, quality improvement or insurance 
datasets.2,4 
 
We sought to describe the feasibility and prognostic validity of using HT at scale in a national 
dataset. 
 
Methods 
Datasets:The datasets used in this project are managed by Information Services Division, NHS 
Scotland.  Access to these data is made through the Information Request Service.  
3 
 
Stroke data were from the Scottish Stroke Care Audit (SSCA).  SSCA has been described previously5, 
in brief, this resource collects patient level data from all Scottish hospitals providing stroke care.  
Participation in the SSCA is mandatory as data are used to improve stroke care.  
 
We performed individual patient level linkage of SSCA to national health and social care datasets 
using Scottish Morbidity Records6 and Mortality data.  These datasets all have robust quality control 
processes.6  A unique patient identifier, the Community Health Index, was used to facilitate the 
linkage.  We quantified length of initial stay (even if across hospitals), readmission (and length of 
subsequent stays), institutionalisation and death.  Using SSCA data for research has been approved 
by Scotland A REC:10/MRE00/76; Privacy Advisory Committee Ref:76/11. 
 
Analyses:We attempted to describe HT for all strokes contained in SSCA, censoring at the standard 
time of 90 days.2  HT follow-up period started on admission date (or onset date for in-hospital 
cases).  HT was the number of full days not in hospital and where discharge destination was same as 
at admission (including where care-home was the pre-stroke residence). 
 
To assess feasibility we described the proportion of stroke events held in SSCA that could have HT 
calculated.  We described prognostic validity by comparing HT to predefined variables known to be 
associated with outcome:age (years); NIHSS (baseline and post thrombolysis); stroke type 
(ischaemic/haemorrhagic) and Six Simple Variables scale (SSV). SSV is a prognostic scale that includes 
pre-stroke living arrangements and independence, and post stroke orientation, arm movement, 
mobility and verbal response.7  We assessed SSV as an ordinal scale, in aggregate and individual 
components, and as a quasi-continuous measure including age.8  SSV is used as a case-mix adjuster 
in trials and has been shown to have excellent prognostic utility.7  Age and NIHSS were combined to 
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calculate SPAN score, another validated prognostic scale.9  We described association for the 
complete group and subgroups of 90-day survivors and those admitted from home.  We correlated 
HT with survival and length of stay.  We used Spearman’s rank correlation with strength of 
association described using conventional categorisations.10  Analyses were performed using SPSS 
software version:21(IBM Corp. Armonk,NY). 
 
Results 
We accessed SSCA data from 2005-2017 inclusive.  Of 102,642 patients, we were able to calculate HT 
for 101,969 (99.3%).  Median age:71 years (IQR:65-83); 51674 (50.7%) female; 81,771 (80.2%) 
ischaemic stroke; 70130 (68.8%) from urban areas; 25,071 (24.6%) from areas of socioeconomic 
deprivation. 
 
Mean HT was 46 days (95%CI:45.8-46.2; range:0-90).  There was significant correlation with all 
prognostic factors.  Correlations ranged from medium to large, with strongest correlation for post-
thrombolysis NIHSS (rho:-0.72[95%CI:-0.77 to -0.70]).  Correlations remained significant in subgroup 
analyses.(Table 1,Figure 1)  HT was associated with individual SSV factors.(Table 2)  Correlations with 
NIHSS after adjusting for age and sex were similar to unadjusted values: Pre-thrombolysis NIHSS, 
rho:-0.51 (-0.53 to -0.49); post-thrombolysis NIHSS, rho:-0.71 (-0.73 to -0.69). 
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Discussion  
We have demonstrated that in a national dataset of over a hundred thousand stroke admissions, it is 
feasible to calculate HT using routinely recorded data.  HT derived in this way correlates with factors 
that predict recovery and should be a reasonable proxy of functional outcome. 
 
Although our study was limited to Scotland, our findings will be relevant to any healthcare system 
that collects stroke and healthcare utilisation data.  Countries with national stroke registries that 
lack resource for post-discharge follow-up may be particularly interested in our findings.  HT offers 
an inexpensive, time efficient method of outcome assessment that can be used for research, audit 
and service planning.  In Scotland we have already started using HT for outcome comparisons across 
stroke centres.(Supplementary material I)  
 
The strengths of our approach include the size of our dataset, giving unparalleled precision in 
analyses.  Our inclusive sampling frame included all patients with stroke treated in a Scottish hospital 
and covers all rural and urban settings and socioeconomic strata.  Our inclusive approach is reflected 
in the range of outcomes demonstrated.  Previous work has suggested that a mean HT of around 50 
days is equivalent to a modified Rankin Scale (mRS) of 32,4.  Thus, our SSCA data suggest a broader 
range of stroke outcomes than usually seen in a clinical trial.  Our findings were robust across a 
series of subgroups, while correlation with length of stay and mortality shows that HT offers 
something more than if using these values alone. 
 
There are limitations to our work.  Assessments of prognosis were limited to baseline factors only, 
albeit baseline factors known to have excellent predictive accuracy.  We did not have full data for all 
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factors of interest, but this further emphasises the difficulty of outcome assessment at scale and the 
potential utility of our HT approach.  However, the consistency of association between HT and all 
prognostic factors is reassuring.  We recognise that comparisons with mRS would be a useful 
assessment of concurrent validity.  Such validations, using trial and registry data, have been 
described and consistently report strong association of HT with mRS.2,4,11  There is no reason to think 
the relationship would differ in larger scale, real-world data.   
 
Granularity of information at the individual patient level was limited and there are plausible 
situations where our derived HT may be erroneous.  For example, our data capture would miss a 
person who is a temporary resident or emigrates following stroke.  We believe such occurrences are 
unusual, only 700 (0.7%) SSCA patients did not have a Scottish postcode.  Admission to care-home 
following discharge may also be missed and methods for capturing care-home admission from 
routine sources are being developed.12  
 
We have demonstrated feasibility and validity of 90 day HT for stroke.  The approach could be easily 
applied to other diseases and other time points.  Use of HT following subarachnoid haemorrhage is 
described13, but the HT concept could be used beyond cerebrovascular disease allowing a ‘big data’ 
approach to other chronic conditions.14 
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Figure and Table Legends 
 
Table 1:Correlation of Home-Time with prognostic factors 
Table 2:Home-time for components of Six Simple Variable score 
Figure 1:Home-time versus SPAN (age plus NIHSS)9 
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Table 1:Correlation of Home-Time with prognostic factors 
 Rank correlation with HT 
Prognostic factor  Total population Survivors only Excluding care-
home residents 
Age (years) 
-0.35 (-0.36 to -0.34) 
N=101,969 
-0.28 (-0.28 to -0.27) 
N=82,045 
-0.34 (-0.35 to -0.34) 
N=92,324 
SSV (ordinal score) 
-0.61 (-0.62 to-0.61) 
N=92,231 
-0.53 (-0.54 to -0.53) 
N=74,812 
-0.61 (-0.61 to-0.60) 
N=84,047 
SSV (quasi-continuous) 
-0.63 (-0.62 to -0.63) 
N=92,231 
-0.55 (-0.56 to -0.55) 
N=74,887 
-0.63 (-0.63 to -0.62) 
N=84,138 
NIHSS 
-0.54 (-0.56 to -0.52) 
N=5,546 
-0.48 (-0.50 to -0.46) 
N=4,445 
-0.54 (-0.60 to -052) 
N=5,252 
NIHSS  
(post-thrombolysis) 
-0.72 (-0.74 to -0.70) 
N=2,877 
-0.70 (-0.72 to -0.68) 
N=2,360 
-0.72 (-0.74 to -0.71) 
N=2,734 
SPAN (age + NIHSS) 
-0.48 (-0.50 to-0.46) 
N=5,546 
-0.38 (-0.40 to -0.35) 
N=4,445 
-0.47 (-0.49 to -0.45)  
N=5,252 
Length of stay  
(days) 
-0.64 (-0.64 to -0.64) 
N=101,858 
-0.90 (-0.90 to -0.90) 
N=81,959 
-0.68 (-0.68 to -0.67) 
N=92,223 
Survival at one year  
 
0.56 (0.55 to 0.56) 
N=95,013 
0.25 (0.24 to 0.26) 
N=76,424 
0.54(0.54 to 0.55) 
N=85,805 
Stroke type   
Ischaemic (N=81,771) 
Haemorrhage(N=11,640) 
Mean HT 
49.3 (49.1 to 49.6) 
26.6 (25.9 to 27.2) 
  
All significant:p<0.001; analyses are rho (95% confidence interval) unless otherwise stated 
HT:Home-Time; SSV:Six Simple Variables  
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Table 2:Home-time for components of Six Simple Variable score 
Prognostic variable 
Present (n) 
Mean HT (95%CI) 
Absent (n) 
Mean HT (95%CI) 
Mean difference HT 
(95%CI) 
Lives alone 
38,152 
41.1 (40.7-41.5) 
60,883 
49.3 (49.0-49.6) 
-8.2  
(-8.7 to -7.7) 
Independent pre-stroke 
81,312 
50.6 (50.3-50.8) 
16,968 
26.0 (25.5-26.5) 
24.6  
(24.0-25.2) 
Orientated 
62,873 
58.8 (58.6-59.1) 
34,884 
24.7 (24.3-25.0) 
34.1  
(33.7-34.6) 
Lift arms 
62,196 
60.5 (60.2-60.8) 
36,512 
22.2 (21.9-22.5) 
38.3  
(37.9-38.7) 
Walking 
43,457 
66.4 (66.1-66.7) 
54,007 
30.0 (29.7-30.3) 
36.4  
(36.0-36.9) 
Talking 
74,488 
54.8 (54.5-55.1) 
25,556 
21.2 (20.8-21.6) 
33.6  
(33.1-34.0) 
All significant:p<0.001 
HT:Home-Time 
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Figure 1:Home-time versus SPAN (age plus NIHSS)9 
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Supplemental Material I  
Comparison of 90 day home-time and annual stroke admissions across all hospitals providing acute 
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